Glaukos beats path to FDA after eye implant trials hit goals

Glaukos has reported wins in a pair of late-phase clinical trials, teeing it up to seek FDA approval of its travoprost intraocular implant next year. The studies found the implant was noninferior to the active control, twice-daily topical timolol ophthalmic solution, in glaucoma and ocular hypertension patients.